Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) rose 10.4% on Thursday . The stock traded as high as $26.09 and last traded at $26.01. Approximately 235,707 shares traded hands during trading, a decline of 83% from the average daily volume of 1,423,980 shares. The stock had previously closed at $23.56.
DYN has been the subject of a number of recent research reports. StockNews.com cut shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They set an "outperform" rating and a $45.00 target price for the company. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Finally, Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $46.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $50.42.
Read Our Latest Stock Report on Dyne Therapeutics
The company's 50 day simple moving average is $28.02 and its 200-day simple moving average is $34.54. The firm has a market cap of $2.58 billion, a P/E ratio of -7.12 and a beta of 1.09.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.
In other news, Director Jason P. Rhodes sold 782 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now owns 15,962 shares in the company, valued at $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares of the company's stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,742 shares of company stock worth $1,443,246. Company insiders own 20.77% of the company's stock.
Several institutional investors have recently bought and sold shares of DYN. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter worth approximately $62,000. Finally, KBC Group NV increased its position in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after purchasing an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.